NAT-APIXABAN TABLET

Kraj: Kanada

Język: angielski

Źródło: Health Canada

Składnik aktywny:

APIXABAN

Dostępny od:

NATCO PHARMA (CANADA) INC

Kod ATC:

B01AF02

INN (International Nazwa):

APIXABAN

Dawkowanie:

2.5MG

Forma farmaceutyczna:

TABLET

Skład:

APIXABAN 2.5MG

Droga podania:

ORAL

Sztuk w opakowaniu:

15G/50G

Typ recepty:

Prescription

Podsumowanie produktu:

Active ingredient group (AIG) number: 0153051001; AHFS:

Status autoryzacji:

APPROVED

Data autoryzacji:

2022-09-20

Charakterystyka produktu

IMPORTANT: PLEASE READ
_Pr_
_NAT-APIXABAN (apixaban) Product Monograph_
_Page 1 of 80 _
_ _
PRODUCT MONOGRAPH
PR
NAT-APIXABAN
Apixaban Tablets
2.5 mg and 5 mg
Anticoagulant
Natco Pharma (Canada) Inc.
Date of Revision:
2000 Argentia Road, Plaza 1, Suite 200
June 18, 2022
Mississauga ON L5N 1P7
Submission
Control No: 260519
_Pr_
_NAT-APIXABAN Product Monograph_
_Page 2 of 80 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................4
ADVERSE REACTIONS
................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
20
DOSAGE AND ADMINISTRATION
.............................................................................
25
OVERDOSAGE
...............................................................................................................
32
ACTION AND CLINICAL PHARMACOLOGY
............................................................33
SPECIAL HANDLING INSTRUCTIONS
......................................................................
38
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................. 38
PART II: SCIENTIFIC INFORMATION
..............................................................................
39
PHARMACEUTICAL INFORMATION
........................................................................
39
CLINICAL TRIALS
.........................................................................................................
40
DETAILED PH